Increased Tumor Response to Neoadjuvant Therapy Among Rectal Cancer Patients Taking Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2016 May 21

PMID 27203227

Citations 28

Authors

Zachary S Morris

Sandeep Saha

William J Magnuson

Brett A Morris

Jenna F Borkenhagen

Alisa Ching

Gayle Hirose

Vanesa McMurry

David M Francis

Paul M Harari

Rick Chappell

Stuart Tsuji

Mark A Ritter

Affiliations

Soon will be listed here.

Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensive medications that have been reported to affect aberrant angiogenesis and the dysregulated inflammatory response. Because of such mechanisms, it was hypothesized that these medications might affect the tumor response to neoadjuvant radiation in patients with rectal cancer.

Methods: One hundred fifteen patients who were treated with neoadjuvant radiation at the University of Wisconsin (UW) between 1999 and 2012 were identified. Univariate analyses were performed with anonymized patient data. In a second independent data set, 186 patients with rectal cancer who were treated with neoadjuvant radiation at the Queen's Medical Center of the University of Hawaii (UH) between 1995 and 2010 were identified. These data were independently analyzed as before. Multivariate analyses were performed with aggregate data.

Results: Among patients taking ACEIs/ARBs in the UW data set, a significant 3-fold increase in the rate of pathologic complete response (pCR) to neoadjuvant therapy (52% vs 17%, P = .001) was observed. This finding was confirmed in the UH data set, in which a significant 2-fold-increased pCR rate (24% vs 12%, P = .03) was observed. Identified patient and treatment characteristics were otherwise balanced between patients taking and not taking ACEIs/ARBs. No significant effect was observed on pCR rates with other medications, including statins, metformin, and aspirin. Multivariate analyses of aggregate data identified ACEI/ARB use as a strong predictor of pCR (odds ratio, 4.02; 95% confidence interval, 2.06-7.82; P < .001).

Conclusions: The incidental use of ACEIs/ARBs among patients with rectal cancer is associated with a significantly increased rate of pCR after neoadjuvant treatment. Cancer 2016;122:2487-95. © 2016 American Cancer Society.

Citing Articles

Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.

Everatt R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, Intaite B, Cicenas S BMC Cancer. 2025; 25(1):38.

PMID: 39780067 PMC: 11707882. DOI: 10.1186/s12885-024-13273-8.

Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis.

Xiao Y, Chen X, Li W, Li X, Zhou W Oncol Lett. 2024; 28(5):534.

PMID: 39290956 PMC: 11406588. DOI: 10.3892/ol.2024.14667.

Renin-Angiotensin Inhibitor, Captopril, Attenuates Growth of Patient-Derived Colorectal Liver Metastasis Organoids.

Riddiough G, Fifis T, Muralidharan V, Christophi C, Tran B, Perini M Int J Mol Sci. 2024; 25(6).

PMID: 38542253 PMC: 10970006. DOI: 10.3390/ijms25063282.

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies.

Hassani B, Attar Z, Firouzabadi N Cancer Cell Int. 2023; 23(1):254.

PMID: 37891636 PMC: 10604988. DOI: 10.1186/s12935-023-03080-9.

Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study.

Laghlam D, Chaba A, Tarneaud M, Charpentier J, Mira J, Pene F Cancers (Basel). 2023; 15(12).

PMID: 37370793 PMC: 10296067. DOI: 10.3390/cancers15123183.

References

Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K . Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010; 103(11):1644-8. PMC: 2994224. DOI: 10.1038/sj.bjc.6605955. View

Kalady M, Campos-Lobato L, Stocchi L, Geisler D, Dietz D, Lavery I . Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009; 250(4):582-9. DOI: 10.1097/SLA.0b013e3181b91e63. View

Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R . Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23(34):8688-96. DOI: 10.1200/JCO.2005.02.1329. View

Lee T, Greene-Schloesser D, Payne V, Diz D, Hsu F, Kooshki M . Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment. Radiat Res. 2012; 178(1):46-56. PMC: 3422865. DOI: 10.1667/rr2731.1. View

Erreni M, Mantovani A, Allavena P . Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron. 2011; 4(2):141-54. PMC: 3170420. DOI: 10.1007/s12307-010-0052-5. View

Sipahi I, Debanne S, Rowland D, Simon D, Fang J . Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7):627-36. PMC: 4070221. DOI: 10.1016/S1470-2045(10)70106-6. View

Abdul-Jalil K, Sheehan K, Kehoe J, Cummins R, OGrady A, McNamara D . The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer. Colorectal Dis. 2013; 16(1):O16-25. DOI: 10.1111/codi.12439. View

Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee S, Madoff R, Rothenberger D . A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003; 46(3):298-304. DOI: 10.1007/s10350-004-6545-x. View

Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T, Ishigai Y . Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res. 2001; 52(2):314-20. DOI: 10.1016/s0008-6363(01)00372-8. View

10.

Okwan-Duodu D, Landry J, Shen X, Diaz R . Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2013; 305(3):R205-15. DOI: 10.1152/ajpregu.00544.2012. View

11.

Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T . Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2004; 130(10):567-73. DOI: 10.1007/s00432-004-0582-7. View

12.

Moulder J, Fish B . Angiotensin converting enzyme inhibitor captopril does not prevent acute gastrointestinal radiation damage in the rat. Radiat Oncol Investig. 1997; 5(2):50-3. DOI: 10.1002/(SICI)1520-6823(1997)5:2<50::AID-ROI2>3.0.CO;2-I. View

13.

Kharofa J, Cohen E, Tomic R, Xiang Q, Gore E . Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 84(1):238-43. DOI: 10.1016/j.ijrobp.2011.11.013. View

14.

van der Knaap R, Siemes C, Coebergh J, Van Duijn C, Hofman A, Stricker B . Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008; 112(4):748-57. DOI: 10.1002/cncr.23215. View

15.

Corvol P, Jeunemaitre X, Charru A, Kotelevtsev Y, Soubrier F . Role of the renin-angiotensin system in blood pressure regulation and in human hypertension: new insights from molecular genetics. Recent Prog Horm Res. 1995; 50:287-308. DOI: 10.1016/b978-0-12-571150-0.50017-2. View

16.

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E . Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009; 135(10):1429-35. DOI: 10.1007/s00432-009-0587-3. View

17.

Chae Y, Valsecchi M, Kim J, Bianchi A, Khemasuwan D, Desai A . Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011; 29(9):585-93. DOI: 10.3109/07357907.2011.616252. View

18.

Moulder J, Fish B, Cohen E . Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol. 1998; 46(3):307-15. DOI: 10.1016/s0167-8140(97)00175-8. View

19.

Wang Q, Lei X, Zhu S, Zhang S . Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts. Dis Esophagus. 2012; 25(8):757-63. DOI: 10.1111/j.1442-2050.2011.01320.x. View

20.

Harder E, Park H, Nath S, Mancini B, Decker R . Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Pract Radiat Oncol. 2015; 5(6):e643-9. DOI: 10.1016/j.prro.2015.07.003. View